![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANXA1 |
Gene summary for ANXA1 |
![]() |
Gene information | Species | Human | Gene symbol | ANXA1 | Gene ID | 301 |
Gene name | annexin A1 | |
Gene Alias | ANX1 | |
Cytomap | 9q21.13 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P04083 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
301 | ANXA1 | GSM4909281 | Human | Breast | IDC | 9.72e-06 | -3.81e-01 | 0.21 |
301 | ANXA1 | GSM4909282 | Human | Breast | IDC | 9.16e-07 | -1.64e-01 | -0.0288 |
301 | ANXA1 | GSM4909285 | Human | Breast | IDC | 6.68e-16 | -5.41e-01 | 0.21 |
301 | ANXA1 | GSM4909286 | Human | Breast | IDC | 3.03e-23 | -8.52e-01 | 0.1081 |
301 | ANXA1 | GSM4909287 | Human | Breast | IDC | 8.76e-03 | -3.28e-01 | 0.2057 |
301 | ANXA1 | GSM4909290 | Human | Breast | IDC | 5.24e-23 | -9.23e-01 | 0.2096 |
301 | ANXA1 | GSM4909291 | Human | Breast | IDC | 1.57e-23 | -1.00e+00 | 0.1753 |
301 | ANXA1 | GSM4909292 | Human | Breast | IDC | 2.62e-07 | -1.08e+00 | 0.1236 |
301 | ANXA1 | GSM4909293 | Human | Breast | IDC | 1.21e-21 | -7.81e-01 | 0.1581 |
301 | ANXA1 | GSM4909294 | Human | Breast | IDC | 1.44e-29 | -8.53e-01 | 0.2022 |
301 | ANXA1 | GSM4909296 | Human | Breast | IDC | 1.71e-36 | -9.89e-01 | 0.1524 |
301 | ANXA1 | GSM4909297 | Human | Breast | IDC | 6.02e-27 | -7.85e-01 | 0.1517 |
301 | ANXA1 | GSM4909298 | Human | Breast | IDC | 1.37e-29 | -8.73e-01 | 0.1551 |
301 | ANXA1 | GSM4909299 | Human | Breast | IDC | 1.47e-07 | 4.25e-01 | 0.035 |
301 | ANXA1 | GSM4909301 | Human | Breast | IDC | 2.31e-49 | -1.06e+00 | 0.1577 |
301 | ANXA1 | GSM4909302 | Human | Breast | IDC | 1.39e-28 | -9.03e-01 | 0.1545 |
301 | ANXA1 | GSM4909303 | Human | Breast | IDC | 5.04e-07 | -8.20e-01 | 0.0438 |
301 | ANXA1 | GSM4909304 | Human | Breast | IDC | 4.09e-44 | -1.05e+00 | 0.1636 |
301 | ANXA1 | GSM4909306 | Human | Breast | IDC | 5.39e-14 | -6.64e-01 | 0.1564 |
301 | ANXA1 | GSM4909307 | Human | Breast | IDC | 1.98e-15 | -6.60e-01 | 0.1569 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00455803 | Oral cavity | EOLP | regulation of T cell differentiation | 33/2218 | 146/18723 | 1.75e-04 | 1.81e-03 | 33 |
GO:004873224 | Oral cavity | EOLP | gland development | 77/2218 | 436/18723 | 2.05e-04 | 2.06e-03 | 77 |
GO:19037075 | Oral cavity | EOLP | negative regulation of hemopoiesis | 26/2218 | 106/18723 | 2.11e-04 | 2.11e-03 | 26 |
GO:00515929 | Oral cavity | EOLP | response to calcium ion | 33/2218 | 149/18723 | 2.62e-04 | 2.54e-03 | 33 |
GO:19021065 | Oral cavity | EOLP | negative regulation of leukocyte differentiation | 25/2218 | 102/18723 | 2.80e-04 | 2.69e-03 | 25 |
GO:00026953 | Oral cavity | EOLP | negative regulation of leukocyte activation | 39/2218 | 187/18723 | 2.89e-04 | 2.74e-03 | 39 |
GO:190210713 | Oral cavity | EOLP | positive regulation of leukocyte differentiation | 34/2218 | 157/18723 | 3.32e-04 | 3.08e-03 | 34 |
GO:190370813 | Oral cavity | EOLP | positive regulation of hemopoiesis | 34/2218 | 157/18723 | 3.32e-04 | 3.08e-03 | 34 |
GO:009030314 | Oral cavity | EOLP | positive regulation of wound healing | 17/2218 | 59/18723 | 3.48e-04 | 3.20e-03 | 17 |
GO:00028193 | Oral cavity | EOLP | regulation of adaptive immune response | 38/2218 | 183/18723 | 3.75e-04 | 3.40e-03 | 38 |
GO:004484321 | Oral cavity | EOLP | cell cycle G1/S phase transition | 47/2218 | 241/18723 | 3.79e-04 | 3.41e-03 | 47 |
GO:00026984 | Oral cavity | EOLP | negative regulation of immune effector process | 26/2218 | 110/18723 | 3.94e-04 | 3.53e-03 | 26 |
GO:004212910 | Oral cavity | EOLP | regulation of T cell proliferation | 36/2218 | 171/18723 | 4.01e-04 | 3.58e-03 | 36 |
GO:00508681 | Oral cavity | EOLP | negative regulation of T cell activation | 28/2218 | 122/18723 | 4.03e-04 | 3.58e-03 | 28 |
GO:003459925 | Oral cavity | EOLP | cellular response to oxidative stress | 54/2218 | 288/18723 | 4.04e-04 | 3.58e-03 | 54 |
GO:0046638 | Oral cavity | EOLP | positive regulation of alpha-beta T cell differentiation | 15/2218 | 50/18723 | 4.75e-04 | 4.16e-03 | 15 |
GO:0042093 | Oral cavity | EOLP | T-helper cell differentiation | 18/2218 | 66/18723 | 4.94e-04 | 4.31e-03 | 18 |
GO:00510517 | Oral cavity | EOLP | negative regulation of transport | 80/2218 | 470/18723 | 5.11e-04 | 4.44e-03 | 80 |
GO:003196024 | Oral cavity | EOLP | response to corticosteroid | 35/2218 | 167/18723 | 5.23e-04 | 4.52e-03 | 35 |
GO:00026974 | Oral cavity | EOLP | regulation of immune effector process | 61/2218 | 339/18723 | 5.48e-04 | 4.68e-03 | 61 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Breast | DCIS |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Breast | IDC |
ANXA1 | FPR2 | ANXA1_FPR2 | ANNEXIN | Cervix | ADJ |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Cervix | ADJ |
ANXA1 | FPR2 | ANXA1_FPR2 | ANNEXIN | Cervix | CC |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Cervix | CC |
ANXA1 | FPR2 | ANXA1_FPR2 | ANNEXIN | Cervix | Healthy |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Cervix | Healthy |
ANXA1 | FPR2 | ANXA1_FPR2 | ANNEXIN | Cervix | Precancer |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Cervix | Precancer |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | CRC | AD |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | CRC | MSI-H |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Endometrium | ADJ |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Endometrium | AEH |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Endometrium | EEC |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | GC | ADJ |
ANXA1 | FPR2 | ANXA1_FPR2 | ANNEXIN | HNSCC | ADJ |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | HNSCC | ADJ |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | HNSCC | Healthy |
ANXA1 | FPR1 | ANXA1_FPR1 | ANNEXIN | Liver | HCC |
Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
ANXA1 | PANIN | Pancreas | Healthy | VIM,LMNA,CAV1, etc. | 2.06e-01 | ![]() |
ANXA1 | LYMEND | Thyroid | ADJ | TPSB2,S100A10,ANXA2, etc. | 4.63e-01 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANXA1 | SNV | Missense_Mutation | novel | c.428C>T | p.Ser143Leu | p.S143L | P04083 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
ANXA1 | SNV | Missense_Mutation | novel | c.37N>C | p.Phe13Leu | p.F13L | P04083 | protein_coding | tolerated(0.4) | benign(0.162) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ANXA1 | SNV | Missense_Mutation | c.80C>T | p.Ser27Leu | p.S27L | P04083 | protein_coding | tolerated(0.15) | benign(0) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
ANXA1 | SNV | Missense_Mutation | novel | c.598G>A | p.Asp200Asn | p.D200N | P04083 | protein_coding | deleterious(0.02) | possibly_damaging(0.71) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
ANXA1 | SNV | Missense_Mutation | novel | c.168N>A | p.Met56Ile | p.M56I | P04083 | protein_coding | deleterious(0.01) | benign(0.04) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
ANXA1 | SNV | Missense_Mutation | c.604G>A | p.Asp202Asn | p.D202N | P04083 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AY-A71X-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ANXA1 | SNV | Missense_Mutation | c.831C>A | p.Phe277Leu | p.F277L | P04083 | protein_coding | deleterious(0.01) | possibly_damaging(0.5) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
ANXA1 | SNV | Missense_Mutation | novel | c.881A>G | p.Lys294Arg | p.K294R | P04083 | protein_coding | tolerated(0.41) | benign(0.021) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ANXA1 | SNV | Missense_Mutation | rs142849845 | c.97N>A | p.Gly33Arg | p.G33R | P04083 | protein_coding | tolerated(0.27) | benign(0.037) | TCGA-CK-4948-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ANXA1 | SNV | Missense_Mutation | c.901N>A | p.Val301Ile | p.V301I | P04083 | protein_coding | deleterious(0.02) | probably_damaging(0.945) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | RIMEXOLONE | RIMEXOLONE | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | CLOCORTOLONE | CLOCORTOLONE | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | PREDNISOLONE | PREDNISOLONE | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | BECLOMETHASONE | BECLOMETHASONE | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | MOMETASONE | MOMETASONE | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | METHYLPREDNISOLONE | METHYLPREDNISOLONE | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | AMCINONIDE | AMCINONIDE | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | PPD | 11468004 | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | CLOBETASOL | CLOBETASOL | ||
301 | ANXA1 | CELL SURFACE, DRUGGABLE GENOME | HYDROCORTISONE | HYDROCORTISONE | 1712816 |
Page: 1 2 3 |